Does carvedilol cause hair loss? This is a question raised by many patients prescribed this widely used beta-blocker for heart failure, hypertension, or left ventricular dysfunction. Carvedilol is listed in UK product information as having alopecia as a recognised, albeit rare, adverse effect. The type of hair loss most commonly associated with carvedilol is telogen effluvium — a diffuse, temporary shedding triggered by pharmacological stress on the hair growth cycle. Understanding the evidence, the likely mechanism, and the practical steps to take can help patients and clinicians make informed, safe decisions together.
Summary: Carvedilol can cause hair loss, recognised in UK product information as a rare or frequency-not-known adverse effect, typically presenting as reversible telogen effluvium.
- Carvedilol is a non-selective beta-blocker with alpha-1 blocking properties, prescribed for heart failure, hypertension, and post-MI left ventricular dysfunction.
- Alopecia is listed in the UK Summary of Product Characteristics (SmPC) for carvedilol, classified as rare (fewer than 1 in 1,000 patients) or of frequency not known.
- The hair loss pattern is typically telogen effluvium — diffuse, non-scarring shedding that begins weeks to months after starting the medication.
- Beta-adrenergic receptors are present in hair follicle cells; blocking them may disrupt follicular cycling, though the exact mechanism is not fully established.
- Hair loss from carvedilol is generally reversible after dose reduction or discontinuation, but medication must never be stopped abruptly due to serious cardiovascular risks.
- Other causes of diffuse hair loss — including hypothyroidism and iron deficiency anaemia — should be excluded via GP blood tests before attributing shedding to carvedilol.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
Can Carvedilol Cause Hair Loss?
Yes, carvedilol can cause hair loss; alopecia is listed in the UK SmPC as a rare or frequency-not-known adverse effect, typically presenting as reversible telogen effluvium beginning weeks to months after starting treatment.
Experiencing these side effects? Our pharmacists can help you navigate them →
Carvedilol is a non-selective beta-blocker with additional alpha-1 blocking properties, commonly prescribed in the UK for conditions such as heart failure, hypertension, and left ventricular dysfunction following a myocardial infarction. It works by blocking the effects of adrenaline on beta-adrenergic receptors in the heart and blood vessels, as well as dilating blood vessels through alpha-1 blockade, thereby reducing heart rate, blood pressure, and the workload placed on the heart.
Hair loss (alopecia) has been reported as an adverse effect of carvedilol and is listed in the Summary of Product Characteristics (SmPC) for carvedilol, as approved by the Medicines and Healthcare products Regulatory Agency (MHRA). Depending on the specific licensed UK product, alopecia is typically classified as rare or of frequency not known. This means it has been recognised in clinical use, though the underlying mechanism is not fully understood, and not everyone taking carvedilol will experience this effect.
The type of hair loss associated with carvedilol is typically telogen effluvium — a diffuse, non-scarring form of hair shedding rather than patchy or permanent loss. This occurs when a physiological or pharmacological stressor disrupts the normal hair growth cycle, pushing more hairs into the resting (telogen) phase simultaneously. Patients may notice increased shedding when washing or brushing their hair, often beginning several weeks to months after starting the medication.
It is worth emphasising that hair loss from carvedilol is generally considered reversible upon dose reduction or discontinuation, though any changes to medication should only be made gradually and under medical supervision. If you are concerned about hair thinning whilst taking carvedilol, it is important not to stop the medication abruptly, as this can carry serious cardiovascular risks.
Not sure if this is normal? Chat with one of our pharmacists →
| Side Effect | Frequency | Severity | Management |
|---|---|---|---|
| Alopecia (diffuse hair shedding / telogen effluvium) | Rare (<1 in 1,000) or frequency not known; varies by licensed product | Mild to moderate; generally non-scarring and reversible | Do not stop carvedilol abruptly; seek GP review for gradual dose adjustment if needed |
| Onset of hair shedding | Reported in post-marketing pharmacovigilance (MHRA, EMA Yellow Card data) | Typically mild; noticeable when washing or brushing hair | Keep a record of onset and pattern; photograph affected areas for GP discussion |
| Rebound hypertension / worsening heart failure (on abrupt withdrawal) | Risk increases with sudden discontinuation | Potentially serious cardiovascular risk | Never stop carvedilol without medical supervision; taper gradually per SmPC and NICE guidance |
| Confounding causes of hair loss (e.g., hypothyroidism, iron deficiency anaemia) | Common in general population; may coexist with carvedilol use | Variable; treatable if identified early | GP to arrange FBC, serum ferritin, and TSH to exclude other causes before attributing to carvedilol |
| Hair loss with alternative beta-blockers (e.g., bisoprolol, nebivolol, propranolol) | Reported across multiple beta-blocker agents; exact prevalence uncertain | Mild; switching does not guarantee resolution | Any switch should be specialist-led, gradual, and to an evidence-based agent per NICE NG106 |
| Scalp symptoms (pain, redness, scaling, pustules) | Not attributed to carvedilol; suggests alternative diagnosis | Potentially serious (e.g., cicatricial alopecia) | Seek prompt medical advice; may require urgent specialist dermatology assessment |
| Hair regrowth after dose reduction or discontinuation | Expected in most cases of drug-induced telogen effluvium | Favourable outcome; timeline varies between individuals | Regrowth typically begins within 3–6 months of dose adjustment; report side effects via MHRA Yellow Card |
How Common Is Hair Loss With Beta-Blockers?
Hair loss with beta-blockers, including carvedilol, is classified as rare (fewer than 1 in 1,000 patients) or of frequency not known, based on post-marketing pharmacovigilance data submitted to the MHRA and EMA.
Hair loss associated with beta-blockers as a drug class has been reported across multiple agents in this category, including propranolol, metoprolol, atenolol, and carvedilol. The exact prevalence is difficult to quantify precisely, as many cases go unreported or are attributed to other causes, and clinical trials are not always powered to detect infrequent dermatological side effects. Much of the available evidence comes from case reports and post-marketing pharmacovigilance data rather than large controlled studies.
Post-marketing surveillance data and pharmacovigilance reports submitted to the MHRA and the European Medicines Agency (EMA) have captured cases of alopecia linked to beta-blocker use. In the UK SmPC for carvedilol, alopecia is typically classified as rare (estimated to affect fewer than 1 in 1,000 patients) or of frequency not known (cannot be estimated from available data). Frequency classifications vary between individual licensed products and between different beta-blockers; patients and clinicians should refer to the specific SmPC for the product prescribed. Individual risk may also be influenced by factors such as:
-
Genetic predisposition to hair loss
-
Underlying medical conditions (e.g., thyroid disorders, iron deficiency anaemia)
-
Concurrent medications that may also affect hair growth
-
Nutritional status and overall health
It is also important to consider that patients prescribed carvedilol often have significant cardiovascular disease, and the physiological stress of serious illness itself can trigger telogen effluvium independently of medication. This makes it challenging to attribute hair loss solely to the drug in all cases. Clinicians and patients should therefore approach the association with nuance, recognising that whilst a causal link is plausible, other contributing factors should be systematically excluded before concluding that carvedilol is the definitive cause.
Why Some Medicines Affect Hair Growth
Beta-blockers may cause hair loss by blocking adrenergic receptors in hair follicle cells, disrupting the normal growth cycle and pushing follicles prematurely into the resting (telogen) phase, resulting in diffuse shedding.
To understand why carvedilol and other beta-blockers may cause hair loss, it is helpful to appreciate the biology of the hair growth cycle. Hair follicles cycle through three main phases: anagen (active growth), catagen (transition), and telogen (resting/shedding). At any given time, approximately 85–90% of scalp hairs are in the anagen phase, with the remainder in telogen. Disruption to this cycle — whether by illness, nutritional deficiency, hormonal change, or medication — can shift a disproportionate number of follicles into the telogen phase, resulting in noticeable shedding two to four months later.
The precise mechanisms by which beta-blockers may contribute to hair loss are not fully established. Several hypotheses have been proposed, though the evidence supporting each remains limited:
-
Adrenergic signalling effects: Beta-adrenergic receptors are present in hair follicle cells. Blocking these receptors may directly alter follicular cycling and the local signalling environment that supports active hair growth. This is considered the most plausible proposed mechanism.
-
Physiological stress response: Like other pharmacological stressors, beta-blockers may trigger a shift of follicles into the telogen phase, resulting in diffuse shedding weeks to months later — consistent with the pattern of telogen effluvium.
-
Androgenic interactions: Some sources have suggested possible interactions with androgen metabolism, though robust evidence for this in the context of beta-blockers is lacking, and this remains speculative.
It is important to note that carvedilol, unlike some other beta-blockers, causes vasodilation through its alpha-1 blocking action rather than vasoconstriction. Mechanisms involving reduced peripheral blood flow are therefore not applicable to carvedilol specifically.
Other classes of medication known to cause drug-induced alopecia include anticoagulants (particularly heparin), retinoids, certain antidepressants, and chemotherapy agents — though the mechanisms and severity differ considerably. Drug-induced hair loss is rarely permanent, and understanding the likely mechanism helps both clinicians and patients make informed decisions about ongoing treatment.
What to Do If You Notice Hair Thinning on Carvedilol
Do not stop carvedilol abruptly; instead, consult your GP, who can arrange blood tests to exclude other causes and discuss whether a gradual dose adjustment is clinically appropriate.
If you begin to notice increased hair shedding or thinning whilst taking carvedilol, the first and most important step is not to stop your medication without medical advice. Carvedilol is prescribed for serious cardiovascular conditions, and abrupt withdrawal can lead to rebound hypertension, worsening heart failure, or even precipitate a cardiac event. Any dose reduction or discontinuation must be carried out gradually and under medical supervision, in line with SmPC guidance and NICE recommendations. Patient safety must remain the priority.
Instead, consider taking the following practical steps:
-
Keep a record of when the hair loss started, how much hair you are losing, and whether it is diffuse or patchy. Photographs can be helpful when discussing the issue with your doctor.
-
Review your overall health: Consider whether you have experienced any recent illness, significant stress, dietary changes, or weight loss, all of which can independently trigger telogen effluvium.
-
Check for other causes: Conditions such as hypothyroidism and iron deficiency anaemia are common and treatable causes of diffuse hair loss in the UK. Your GP can arrange baseline blood tests, typically including a full blood count (FBC), serum ferritin, and thyroid-stimulating hormone (TSH). Further tests, such as vitamin D or other investigations, may be arranged if clinically indicated based on your history and risk factors.
-
Assess your hair care routine: Excessive heat styling, tight hairstyles, or harsh chemical treatments can worsen hair fragility and shedding.
Whilst waiting for a medical review, gentle hair care practices — such as using mild shampoos, avoiding tight ponytails, and minimising heat exposure — may help reduce additional mechanical stress on already vulnerable follicles.
Seek prompt medical advice if hair loss is rapid, patchy, or accompanied by scalp symptoms such as pain, redness, scaling, or pustules, or by other symptoms such as fatigue or unexplained weight changes, as these may indicate a different underlying cause requiring earlier assessment. If carvedilol is confirmed as the likely cause, hair regrowth typically begins within three to six months of dose adjustment or discontinuation, though this timeline varies between individuals.
Speaking to Your GP or Pharmacist About Side Effects
Your GP can arrange baseline blood tests, review your medication regimen, and discuss safe options; you can also report suspected side effects to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.
Open communication with your GP or community pharmacist is essential if you suspect carvedilol is contributing to hair loss. Both are well-placed to help you navigate this concern safely and effectively. In the UK, your GP can arrange relevant blood tests to exclude other causes of alopecia (including FBC, ferritin, and TSH as a baseline), review your current medication regimen, and discuss whether any adjustments are appropriate given your cardiovascular history.
When attending your appointment, it can be helpful to:
-
Bring a list of all current medications, including over-the-counter products and supplements, as some (such as high-dose vitamin A or certain herbal remedies) can themselves contribute to hair loss.
-
Mention the timeline of when hair loss began relative to starting or changing the dose of carvedilol.
-
Describe any associated scalp symptoms, such as tenderness, redness, scaling, or pustules, which may suggest a scarring (cicatricial) alopecia requiring more urgent specialist assessment.
Your pharmacist can also provide valuable guidance on whether any other medications you are taking might be contributing to the problem, and can liaise with your GP if a medication review is warranted. NICE guidance on medicines optimisation (NG5) encourages shared decision-making between patients and clinicians, meaning your concerns about quality of life — including the psychological impact of hair loss — are entirely valid and should be taken seriously in any clinical discussion.
If you believe carvedilol has caused a side effect, you can report this directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. This voluntary reporting system is open to both patients and healthcare professionals and helps regulators monitor the real-world safety of medicines.
Alternatives and Next Steps If Hair Loss Continues
If carvedilol is confirmed as the cause, a specialist may consider gradual dose reduction or a supervised switch to another evidence-based beta-blocker such as bisoprolol or nebivolol, in line with NICE guidance.
If a thorough clinical review confirms that carvedilol is the likely cause of your hair loss and the impact on your quality of life is significant, your GP or cardiologist may consider whether an alternative approach is appropriate. It is important to understand that switching beta-blockers does not guarantee resolution, as hair loss is a reported effect across multiple agents in this class. However, some patients tolerate certain beta-blockers better than others, and individual responses can vary.
Possible clinical considerations may include:
-
Dose reduction: If clinically safe, lowering the dose of carvedilol may reduce the severity of the side effect whilst maintaining cardiovascular benefit. Any reduction should be gradual and supervised.
-
Alternative beta-blockers: In conditions such as chronic heart failure or post-myocardial infarction left ventricular dysfunction, any switch should be specialist-led and to another evidence-based beta-blocker with proven mortality benefit — such as bisoprolol or nebivolol — with careful, gradual titration in line with NICE NG106 and the relevant SmPC. Evidence that cardioselective agents carry a meaningfully lower risk of alopecia is limited and not conclusive.
-
Alternative drug classes: Depending on the indication, your cardiologist may explore whether other agents (such as an ACE inhibitor or ARB) could fulfil a complementary therapeutic role. However, it is important to understand that these do not replicate the prognostic benefits of beta-blockade in heart failure or post-MI settings, and any such decision must be made by a specialist with reference to NICE guidance (e.g., NG106 for heart failure, NG136 for hypertension).
For patients in whom hair loss persists despite medication review, referral to an NHS dermatologist may be appropriate. A dermatologist can perform a more detailed assessment, including trichoscopy or scalp biopsy if indicated, and advise on evidence-based treatments for drug-induced or other forms of alopecia. The British Association of Dermatologists (BAD) and Primary Care Dermatology Society (PCDS) provide further resources on telogen effluvium and diffuse hair loss for both clinicians and patients.
Ultimately, the decision to change or continue carvedilol must be made collaboratively, weighing the cardiovascular benefits — which are substantial and well-evidenced — against the impact of side effects on daily life. With the right support from your healthcare team, a safe and satisfactory management plan can almost always be found.
Frequently Asked Questions
How long after starting carvedilol does hair loss usually begin?
Hair loss associated with carvedilol typically begins two to four months after starting the medication, which is consistent with the pattern of telogen effluvium. This delay occurs because the hair follicles are pushed into the resting phase at the time of the pharmacological stress, but the shedding only becomes visible once those hairs reach the end of the telogen phase.
Will my hair grow back if I stop taking carvedilol?
Hair loss caused by carvedilol is generally considered reversible, with regrowth typically beginning within three to six months of dose reduction or discontinuation. However, you must never stop carvedilol abruptly, as this can cause serious cardiovascular complications; any changes must be made gradually under medical supervision.
Is hair loss from carvedilol different to normal hair shedding?
Carvedilol-related hair loss typically presents as diffuse, increased shedding across the whole scalp rather than patchy or localised bald spots, which is characteristic of telogen effluvium. If you notice patchy loss, scalp pain, redness, or scaling, these features suggest a different cause and warrant prompt medical assessment.
Can I switch from carvedilol to bisoprolol to stop hair loss?
Switching to bisoprolol does not guarantee resolution of hair loss, as alopecia is a reported effect across multiple beta-blockers and individual responses vary. Any switch must be specialist-led, gradual, and guided by NICE recommendations, as both agents have specific evidence bases for different cardiovascular indications.
Could something other than carvedilol be causing my hair to thin?
Yes — common and treatable conditions such as hypothyroidism, iron deficiency anaemia, and significant physiological stress can all cause diffuse hair thinning independently of medication. Your GP can arrange baseline blood tests, including a full blood count, serum ferritin, and TSH, to help identify or exclude these causes before attributing the hair loss to carvedilol.
How do I report a hair loss side effect from carvedilol in the UK?
You can report suspected side effects from carvedilol, including hair loss, directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk, which is open to both patients and healthcare professionals. Reporting helps regulators monitor the real-world safety of medicines and contributes to updated guidance for future patients.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
